The news of B of A Securities maintaining a Buy rating and raising the price target for Intellia Therapeutics is positive for the company's stock. This indicates that the analyst believes the stock has potential for growth and is a good investment. This news is highly relevant to NTLA as it directly pertains to the company's stock and is important for investors to consider. The confidence in this analysis is high as it is based on the expert opinion of a B of A Securities analyst.